HomeInsightsStock Comparison

Cipla Ltd vs Mankind Pharma Ltd Stock Comparison

Cipla Ltd vs Mankind Pharma Ltd Stock Comparison

Last Updated on: Aug 03, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1600 as of 02 Aug 11:09.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 22.1 on March 2025 . This represents a CAGR of 0.08% over 6 yearsThe P/E Ratio of Mankind Pharma Ltd changed from 48.1 on March 2024 to 50.2 on March 2025 . This represents a CAGR of 2.16% over 2 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 116434 crore on March 2025 . This represents a CAGR of 22.71% over 6 yearsThe Market Cap of Mankind Pharma Ltd changed from ₹ 92029 crore on March 2024 to ₹ 99973 crore on March 2025 . This represents a CAGR of 4.23% over 2 years.
  • The revenue of Cipla Ltd for the Jun '25 is ₹ 7216 crore as compare to the Mar '25 revenue of ₹ 7019 crore. This represent the growth of 2.8% The revenue of Mankind Pharma Ltd for the Jun '25 is ₹ 3653 crore as compare to the Mar '25 revenue of ₹ 3333 crore. This represent the growth of 9.61%.
  • The ebitda of Cipla Ltd for the Jun '25 is ₹ 2036 crore as compare to the Mar '25 ebitda of ₹ 1827 crore. This represent the growth of 11.47% The ebitda of Mankind Pharma Ltd for the Jun '25 is ₹ 929.82 crore as compare to the Mar '25 ebitda of ₹ 932.5 crore. This represent the decline of -0.29%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1292 crore over 9 quarters. This represents a CAGR of 12.23% The net profit of Mankind Pharma Ltd changed from ₹ 494.19 crore to ₹ 444.62 crore over 9 quarters. This represents a CAGR of -4.59% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.05 % on March 2025 . This represents a CAGR of 9.87% over 6 yearsThe Dividend Payout of Mankind Pharma Ltd changed from 31.56 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Mankind Pharma Ltd

  • Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi.
  • Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006. The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products.
  • It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory.

Cipla Ltd News Hub

News

Cipla gains after Q1 PAT rises 10% YoY to Rs 1,298 crore

Profit before tax (PBT) stood at Rs 1,769.93 crore in Q1 FY26, marking an 9.84% increase f...

Read more

25 Jul 2025 15:25

News

Cipla to conduct board meeting

Cipla will hold a meeting of the Board of Directors of the Company on 25 July 2025. Powere...

Read more

02 Jul 2025 10:19

News

Cipla allots 43,396 equity shares under ESOP

Cipla has allotted 43,396 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

27 Jun 2025 11:02

News

Cipla Ltd spurts 0.42%, up for fifth straight session

Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1517.2, up ...

Read more

11 Jun 2025 13:00

News

Jay Precision Pharmaceuticals acquires 26% stake in AMPIN Energy C&I Eighteen

Jay Precision Pharmaceuticals, subsidiary of Cipla, has completed acquisition of 26% stake...

Read more

29 May 2025 18:48

News

Cipla announced incorporation of subsidiary - CiplaRna GmbH' in Germany

Cipla announced that Cipla (EU), UK, a wholly owned subsidiary of the Company, has incorpo...

Read more

29 May 2025 18:50

Mankind Pharma Ltd News Hub

News

Board of Mankind Pharma recommends Interim Dividend

Mankind Pharma announced that the Board of Directors of the Company at its meeting held on...

Read more

31 Jul 2025 17:41

News

Mankind Pharma to convene board meeting

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 31 July 202...

Read more

15 Jul 2025 10:48

News

Mankind Pharma Ltd spurts 2.92%, gains for five straight sessions

Mankind Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 265...

Read more

14 Jul 2025 13:00

News

Mankind Pharma AGM scheduled

Mankind Pharma announced that the 34th Annual General Meeting(AGM) of the company will be ...

Read more

04 Jul 2025 16:31

News

Mankind Pharma allots 57,709 equity shares under ESOP

Mankind Pharma has allotted 57,709 equity shares of face value of Re. 1/- each of the Comp...

Read more

10 Jun 2025 13:26

News

Mankind Pharma Ltd slips for fifth straight session

Mankind Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs ...

Read more

23 May 2025 13:35

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Mankind Pharma Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Mankind Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Mankind Pharma Ltd

Which company has a larger market capitalization, Cipla Ltd or Mankind Pharma Ltd?

Market cap of Cipla Ltd is 121,259 Cr while Market cap of Mankind Pharma Ltd is 105,753 Cr

What are the key factors driving the stock performance of Cipla Ltd and Mankind Pharma Ltd?

The stock performance of Cipla Ltd and Mankind Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Mankind Pharma Ltd?

As of August 3, 2025, the Cipla Ltd stock price is INR ₹1501.2. On the other hand, Mankind Pharma Ltd stock price is INR ₹2562.3.

How do dividend payouts of Cipla Ltd and Mankind Pharma Ltd compare?

To compare the dividend payouts of Cipla Ltd and Mankind Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions